Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.08.2018 | Case report

Ipilimumab/nivolumab/pembrolizumab

Thyroiditis and endocrine disorders: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

In a case series, 4 women aged 22−57 years developed concurrent or consecutive hypophysitis and thyroiditis following administration of ipilimumab, nivolumab or pembrolizumab [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. …
Literatur
Zurück zum Zitat Snaith J, et al. Unusual patterns of endocrine irAEs in patients receiving checkpoint inhibitor immunotherapies. Clinical Endocrinology 89 (Suppl. 1): 82, Jun 2018 [abstract] - Australia Snaith J, et al. Unusual patterns of endocrine irAEs in patients receiving checkpoint inhibitor immunotherapies. Clinical Endocrinology 89 (Suppl. 1): 82, Jun 2018 [abstract] - Australia
Metadaten
Titel
Ipilimumab/nivolumab/pembrolizumab
Thyroiditis and endocrine disorders: 4 case reports
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-50039-9

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Quinine

Case report

Carbimazole